4-Amino-Imidazoquinoline Compound and Uses thereof
Specific 4-amino-imidazoquinoline compounds act as TLR7 and TLR8 dual agonists, addressing the need for improved potency and cytokine profiles to treat viral infections, cancer, allergic diseases, and liver diseases by enhancing immune activation.
Patent Information
- Application Number
- KR1020227017776
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-10-29
- Filing Date
- 2020-10-20
- Publication Date
- 2026-11-06
- Estimated Expiration
- 2040-10-20
AI Technical Summary
There is a need to develop Toll-like receptor (TLR) 7 and/or TLR8 agonists with improved potency and cytokine profiles for enhancing immune responses against viral infections, cancer, allergic diseases, and liver diseases.
Development of specific 4-amino-imidazoquinoline compounds or their pharmaceutically acceptable salts, which act as TLR7 and TLR8 dual agonists, with varying substituents on R1, R2, and R3 groups, including hydroxy, alkyl, haloalkyl, and alkoxy groups, to enhance immune activation.
The compounds effectively stimulate immune responses, providing therapeutic benefits in treating viral infections, cancer, allergic diseases, and liver diseases by activating TLR7 and TLR8 pathways.
Smart Images

Figure 112022055545428-PCT00022_ABST
Abstract
Description
Technology Field
[0001] The present invention relates generally to Toll-like receptor (TLR) agonists, more specifically to TLR7 and TLR8 dual agonists. Background Technology
[0002] Toll-like receptors (TLRs) are pathogen recognition receptors that play a crucial role in activating both innate and adaptive immunity. Several TLRs have been identified in humans and mice. Some TLRs are found to be located on the cell surface (e.g., TLR 1, 2, 4, 5, and 6), while others are found to be located in endosome compartments (e.g., TLR 3, 7, 8, and 9). TLRs are expressed on different immune cells, particularly monocytes, dendritic cells (DCs), and macrophages. Activation of TLRs results in cytokine secretion (e.g., IFN-α, TNF-α, and IL-12), increased phagocytosis by macrophages, and cytolytic activity by natural killer (NK) cells. TLR activation also leads to enhanced antigen presentation, thereby causing antigen-specific CD8 + It activates an adaptive immune response including cytotoxic T lymphocytes.
[0003] Small molecule TLR 7 and / or TLR 8 agonists have been identified in U.S. Patents No. 8728486, No. 9334268, No. 9884866 and U.S. Patent Publication No. 20190062329. There is still a need to develop TLR7 and / or TLR8 agonists, particularly TLR 7 / 8 agonists, having improved potency and / or cytokine profiles.
[0004] In one aspect, the present invention relates to a compound of the following formula (I) or a pharmaceutically acceptable salt thereof:
[0005]
[0006] During the meal,
[0007] R1 is hydroxy, hydroxy-C 1-6 -alkyl, C 1-6 - Alkoxy or C 1-6 -Alkoxy-C 1-6 -alkyl and;
[0008] R2 is C 1-6 -alkyl, C 1-6 -haloalkyl, C 1-6 -haloalkyl-OC 1-6 -alkyl, C 1-6 -haloalkyl-SC 1-6 -alkyl or hydroxy-C 1-6 -alkyl and; and
[0009] R3 is hydrogen, hydroxyl, halogen, C 1-6 -alkyl, hydroxy-C 1-6 -alkyl, C 1-6 -haloalkyl, C 1-6 - Alkoxy or C 1-6 -Alkoxy-C 1-6 - Becomes alkyl;
[0010] C 1-6 -alkyl, hydroxy-C 1-6 -alkyl, C 1-6 -Alkoxy, C 1-6 -Alkoxy-C 1-6 -alkyl, C 1-6 -haloalkyl and C 1-6 -haloalkyl-SC 1-6 -alkyl groups are each independently unsubstituted or substituted with at least one substituent; the substituents are -NH2, aryl, C 1-6 -alkyl and C 1-6 Each is independently selected from the group consisting of -alkyl-aryls;
[0011] step,
[0012] If R1 is 2-hydroxy-2-methylpropyl, R2 is not methyl, ethyl, butyl, or hydroxymethyl; if R1 is dimethyl-hydroxymethyl, R2 is not isobutyl.
[0013] In another aspect, the present invention relates to a compound of the following formula (II) or a pharmaceutically acceptable salt thereof:
[0014]
[0015] In the formula, R1 and R2 are as defined above.
[0016] In one embodiment of the present invention, R1 is hydroxy-C 1-6 -alkyl or C 1-6 -Alkoxy-C 1-6 - It is an alkyl.
[0017] In another embodiment, R1 is hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, 4-hydroxybutyl, or 2-hydroxy-2-methylpropyl.
[0018] Additionally, in another embodiment, R1 is methoxymethyl, 2-methoxyethyl, ethoxymethyl, or 2-ethoxyethyl.
[0019] In another embodiment, R2 is a straight chain or branched chain C 1-6 - It is an alkyl.
[0020] In another embodiment, R2 is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, 1-methylbutyl, tert-pentyl, neopentyl, n-hexyl, 3-hexyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2-methyl-3-pentyl, 3-methyl-3-pentyl, 2,2-dimethyl-1-butyl, 2,3-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, 2,3-dimethyl-2-butyl, or 3,3-dimethyl-2-butyl.
[0021] In another embodiment, R2 is sec-butyl, tert-butyl, or 3,3-dimethyl-1-butyl.
[0022] In another embodiment, R2 is C 1-6 -Monohaloalkyl, C 1-6 -Dihaloalkyl or C 1-6 - It is a trihaloalkyl.
[0023] In another embodiment, R2 is trifluoromethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, 4,4,4-fluorobutyl, 5,5,5-trifluoropentyl, 6,6,6-trifluorohexyl, 3,3,3-trifluoro-2-methylpropyl, 4,4,4-trifluoro-3-methylbutyl, or 5,5,5-trifluoro-4-methylpentyl.
[0024] In another embodiment, R2 is -CH2-CH2-O-CH2-CF3, -CH2-CH2-O-CH2-CH2-CF3, -CH2-O-CH2-CF3, -CH2-O-CH2-CH2-CF3, or -CH2-O-CH2-CH2-CH2-CF3. In another embodiment, R2 is C 1-6 -haloalkyl-OC 2-6 - It is an alkyl.
[0025] In another embodiment, R2 is -CH2-CH2-S-CH2-CF3, -CH2-CH2-S-CH2-CH2-CF3, -CH2-S-CH2-CF3, -CH2-S-CH2-CH2-CF3 or -CH2-S-CH2-CH2-CH2-CF3.
[0026] In another embodiment, R2 is 2-hydroxyethyl, 3-hydroxypropyl, or 4-hydroxybutyl.
[0027] In another embodiment, R3 is C 1-6 - It is a haloalkyl. C 1-6 - The haloalkyl group can be a trifluoroalkyl group.
[0028] In another embodiment, R3 is H, OH, F, Cl, Br, I, or trifluoromethyl.
[0029] In another embodiment, R1 is 2-hydroxy-2-methylpropyl, and R2 is n-propyl, isobutyl, n-pentyl, isopentyl, 4-methylpentyl, trifluoromethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, 4,4,4-fluorobutyl, 5,5,5-trifluoropentyl, 6,6,6-trifluorohexyl, 3,3,3-trifluoro-2-methylpropyl, 4,4,4-trifluoro-3-methylbutyl, 5,5,5-trifluoro-4-methylpentyl, -CH2-S-CH2-CF3, -CH2-S-CH2-CH2-CF3, -CH2-S-CH2-CH2-CH2-CF3, 2-hydroxyethyl, 3-hydroxypropyl, or 4-hydroxybutyl.
[0030] In another embodiment, R1 is 2-hydroxy-2-methylpropyl and R2 is n-propyl, isobutyl, n-pentyl, 4,4,4-fluorobutyl, 5,5,5-trifluoropentyl or 3,3,3-trifluoro-2-methylpropyl.
[0031] In another embodiment, R1 is 2-hydroxy-2-methylpropyl, R2 is n-propyl, isobutyl, n-pentyl, 4,4,4-fluorobutyl, 5,5,5-trifluoropentyl or 3,3,3-trifluoro-2-methylpropyl, and R3 is H.
[0032] In another embodiment of the present invention, the compound of formula (I) is selected from the compounds listed in Table 2 of the present application.
[0033] In another embodiment, the compound of formula (I) according to the present invention is selected from the group consisting of the following:
[0034] 1-(4-amino-2-propyl-1 H -Imidazoo[4,5-c]quinoline-1-yl)-2-methylpropan-2-ol(compound 1 );
[0035] 1-(4-amino-2-pentyl-1 H -Imidazoo[4,5-c]quinoline-1-yl)-2-methylpropan-2-ol(compound 2);
[0036] 1-(4-amino-2-isobutyl-1 H -Imidazoo[4,5-c]quinoline-1-yl)-2-methylpropan-2-ol(compound 3 );
[0037] 1-(4-amino-2-(4,4,4-trifluorobutyl)-1 H -Imidazoo[4,5-c]quinoline-1-yl)-2-methylpropan-2-ol(compound 9 );
[0038] 1-(4-amino-2-(5,5,5-trifluoropentyl)-1 H -Imidazoo[4,5-c]quinoline-1-yl)-2-methylpropan-2-ol(compound 10 ); and
[0039] 1-(4-amino-2-(3,3,3-trifluoro-2-methylpropyl)-1 H -Imidazoo[4,5-c]quinoline-1-yl)-2-methylpropan-2-ol(compound 12 ).
[0040] An additional aspect of the present invention is a process for preparing a compound of formula (I).
[0041] In another aspect, the present invention relates to a pharmaceutical composition comprising a compound of formula (I) as defined above or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier and / or adjuvant.
[0042] In another aspect, the present invention relates to the use of a compound according to the present invention or a pharmaceutically acceptable salt thereof in the manufacture of a medicine for treating viral infections, cancer, allergic diseases or liver diseases in subjects requiring treatment for these conditions.
[0043] The present invention also relates to a method for treating viral infections, cancer, allergic diseases or liver diseases, wherein the method comprises the step of administering a therapeutically effective amount of a compound of formula (I) according to the present invention or a pharmaceutically acceptable salt thereof to a subject requiring treatment.
[0044] The present invention also relates to a compound of formula (I) according to the present invention or a pharmaceutically acceptable salt thereof for use in treating viral infections, cancer, allergic diseases, or liver diseases in subjects requiring treatment.
[0045] In another embodiment, the viral infection is a hepatitis C virus (HCV), hepatitis B virus (HBV), hepatitis D virus (HDV), human papillomavirus (HPV), or herpes simplex virus 1 (HSV-1) or herpes simplex virus 2 (HSV-2) related infection.
[0046] In one embodiment, the cancer is selected from the group consisting of the esophagus, stomach, colon, rectum, pancreas, lung, breast, cervix, uterine body, ovary, bladder, head and neck, endometrium, osteosarcoma, prostate, and neuroblastoma.
[0047] In another embodiment, the cancer is a HER2-positive cancer or a PD-1-positive cancer.
[0048] In another embodiment, the allergic disease is allergic rhinitis (AR) or asthma.
[0049] In another embodiment, the liver disease is alcoholic fatty liver disease or non-alcoholic fatty liver disease (NAFLD). NAFLD is selected from the group consisting of steatosis, non-alcoholic fatty liver disease (NASH), NASH-related fibrosis, and NASH-related cirrhosis.
[0050] In addition, in another aspect, the present invention relates to the use of a compound according to the present invention or a pharmaceutically acceptable salt thereof in the manufacture of a medicine for treating a disease or pathological condition, wherein activation of TLR7 and / or TLR8 provides a benefit to a subject requiring treatment.
[0051] In another aspect, the present invention relates to the use of a compound according to the present invention or a pharmaceutically acceptable salt thereof in the manufacture of a medicine for activating an immune response effective against viral infections, tumors, allergic diseases, or liver diseases in subjects requiring immune response activation.
[0052] These and other aspects will become apparent from the following description of preferred embodiments taken together with the following drawings, but variations and modifications thereof may be influenced without departing from the spirit and scope of the novel concept of the present disclosure.
[0053] The accompanying drawings illustrate one or more embodiments of the present invention and serve to explain the principles of the present invention together with the described description. Where possible, the same reference numerals are used throughout the drawings to refer to the same or similar components of the embodiments. Brief explanation of the drawing
[0054] FIGS. 1A to 1C show test compounds at various concentrations (compounds 2 , 9 and 10 ) and reference compounds( Reference 1 inside 3 Illuminates the relative IL-6 induction from human PBMCs stimulated by ). Compound Reference 1 It is resiquimod (TLR7 / 8 dual agonist). Compound Reference 2 is 1-(4-amino-2-butyl-1 H - It is imidazo[4,5-c]quinoline-1-yl)-2-methylpropan-2-ol (TLR7 / 8 dual agonist). Compound Reference 3It is VTX2337 (TLR8 agonist). FIGS. 2A to 2C illustrate the relative IL-12p70 induction from human PBMCs stimulated with test compounds and reference compounds at various concentrations. The test compounds and reference compounds are the same as those in FIGS. 1A to 1C. FIGS. 3A to 3C illustrate the relative IP-10 induction from human PBMCs stimulated with test compounds and reference compounds at various concentrations. The test compounds and reference compounds are the same as those in FIGS. 1A to 1C. Specific details for implementing the invention
[0055] definition
[0056] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the present invention pertains. Furthermore, the following definitions are provided to explain and define the meaning and scope of various terms used to describe the present invention.
[0057] The nomenclature used in this application is based on the IUPAC system of nomenclature unless otherwise indicated.
[0058] As used herein, the singular form refers to one or more (i.e., at least one) of the grammatical objects of an item. For example, "component" means one component or more than one component. Furthermore, the use of the term "including" as well as other forms, such as "include," "includes," and "included," is not limited.
[0059] The term "hydroxy" or "hydroxyl" means -OH group.
[0060] The term "alkyl" refers to a branched or straight-chain monovalent saturated aliphatic hydrocarbon radical having 1 to 20 carbon atoms, particularly 1 to 16 carbon atoms, more specifically 1 to 10 carbon atoms, alone or in combination with other groups. The term "alkyl" also encompasses lower alkyl groups as described below.
[0061] The term "lower alkyl" or "C 1-6 "-alkyl" means a straight-chain or branched-chain alkyl group having 1 to 6 carbon atoms, alone or in combination, in particular, a straight-chain or branched-chain alkyl group having 1 to 5 carbon atoms, and more specifically, a straight-chain or branched-chain alkyl group having 1 to 4 carbon atoms. Straight-chain and branched C 1-6 Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl isomers (e.g., n-pentyl, isopentyl, 1-methylbutyl, tert-pentyl, neopentyl) and hexyl isomers (e.g., n-hexyl, 3-hexyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2-methyl-3-pentyl, 3-methyl-3-pentyl, 2,2-dimethyl-1-butyl, 2,3-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, 2,3-dimethyl-2-butyl or It is 3,3-dimethyl-2-butyl). Methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, n-hexyl, 4-methyl-1-pentyl and 3,3-dimethyl-1-butyl are preferred.
[0062] term "hydroxy-C" 1-6 "-alkyl" refers to a lower alkyl group as defined above, in which at least one of the hydrogen atoms of the lower alkyl group is replaced by a hydroxyl group. Hydroxy-C of particular interest 1-6-Among the alkyl groups are hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, 4-hydroxybutyl, or 2-hydroxy-2-methylpropyl. In one embodiment, hydroxy-C 1-6 The alkyl group is 2-hydroxy-2-methylpropyl.
[0063] Term "C 1-6 "-alkoxy" refers to an R'-O- group, where R' is a lower alkyl as defined above. C 1-6 Examples of alkoxy groups are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, and tert-butoxy. Methoxy, ethoxy, or n-propoxy is preferred.
[0064] Term "C 1-6 -Alkoxy-C 1-6 "-alkyl" is defined such that at least one of the hydrogen atoms of the lower alkyl group is C as defined above. 1-6 - Refers to a lower alkyl group replaced by an alkoxy group. C of particular interest 1-6 -Alkoxy-C 1-6 Among the alkyl groups are methoxymethyl, 2-methoxyethyl, ethoxymethyl, and 2-ethoxyethyl, and of particular interest is ethoxymethyl.
[0065] The terms “halo” or “halogen” refer to a fluorine (F), chlorine (Cl), bromine (Br), or iodine (I) atom, either alone or as part of another substituent, unless otherwise noted. More specifically, halogen refers to fluorine or chlorine. Most specifically, halogen refers to fluorine. Additionally, terms such as “haloalkyl” include monohaloalkyl and polyhaloalkyl.
[0066] Term "C 1-6 -haloalkyl" or "halogen-C" 1-6 "-alkyl" refers to a lower alkyl group as defined above, in which at least one of the hydrogen atoms of the lower alkyl group is replaced by at least one halogen atom. In particular, C 1-6- The haloalkyl group is C 1-6 -Monohaloalkyl, C 1-6 -Dihaloalkyl or C 1-6 - It is a trihaloalkyl. More specifically, C 1-6 - The haloalkyl group is C 1-6 It is a trihaloalkyl. C of particular interest 1-6 Among the haloalkyl groups are trifluoromethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, 4,4,4-fluorobutyl, 5,5,5-trifluoropentyl, 6,6,6-trifluorohexyl, 3,3,3-trifluoro-2-methylpropyl, 4,4,4-trifluoro-3-methylbutyl and 5,5,5-trifluoro-4-methylpentyl, and there is particular interest in 4,4,4-fluorobutyl, 5,5,5-trifluoropentyl or 3,3,3-trifluoro-2-methylpropyl.
[0067] Term "C 1-6 -haloalkyl-OC 1-6 -alkyl" or "C 1-6 -haloalkoxy-C 1-6 "-alkyl" means that one of the hydrogen atoms of the lower alkyl group is C 1-6 - Refers to a lower alkyl group as defined above, replaced by a haloalkoxy group. For example, C 1-6 -haloalkyl-OC 1-6 The alkyl group can be -CH2-CH2-O-CH2-CF3, -CH2-CH2-O-CH2-CH2-CF3, -CH2-O-CH2-CF3, -CH2-O-CH2-CH2-CF3, or -CH2-O-CH2-CH2-CH2-CF3.
[0068] Term "C 1-6 -haloalkyl-SC 1-6 -alkyl" or "C 1-6 -haloalkylthio-C 1-6 "-alkyl" means that one of the hydrogen atoms of the lower alkyl group is C 1-6 - It refers to a lower alkyl group as defined above, replaced by a haloalkylthio group. For example, C 1-6 -haloalkyl-SC 1-6The alkyl group can be -CH2-CH2-S-CH2-CF3, -CH2-CH2-S-CH2-CH2-CF3, -CH2-S-CH2-CF3, -CH2-S-CH2-CH2-CF3, or -CH2-S-CH2-CH2-CH2-CF3.
[0069] Term "C 1-6 " and "(C1-C6)" are mutually compatible.
[0070] "C 1-6 " or "(C1-C6)" means that all integer unit quantities within the range of 1 to 6 are specifically disclosed as part of the present invention. Accordingly, quantities of units C1, C2, C3, C4, C5, C6; (C1-C2), (C1-C3), (C1-C4), (C1-C5), (C1-C6); (C2-C3), (C2-C4), (C2-C5), (C2-C6); (C3-C4), (C3-C5), (C3-C6); (C4-C5), (C4-C6); and (C5-C6) are included as embodiments of the present invention.
[0071] The term "substituent" means an atom or group of atoms that replaces a hydrogen atom on the parent molecule.
[0072] The term "aryl" means a polyunsaturated, aromatic, hydrocarbon substituent that may be fused together (i.e., condensed ring aryl) or covalently linked single ring or multiple ring (preferably 1 to 3 rings). A condensed ring aryl refers to a multiple ring condensed together in which at least one of the condensed rings is an aryl ring.
[0073] The compound of formula (I) may form a pharmaceutically acceptable salt. The term “pharmaceutically acceptable salt” refers to the salt that retains the biological efficacy and properties of a free base or free acid that is not biological or otherwise undesirable. Pharmaceutically acceptable salts include, for example, both acid addition salts and base addition salts of the compound of formula (I). The salt is, for example, an acid addition salt with a physiologically suitable inorganic acid, e.g., hydrochloric acid, hydrobromide, nitric acid, carbonic acid, sulfuric acid, sulfite, or phosphoric acid; or an acid addition salt with an organic acid, e.g., methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, formic acid, acetic acid, propionic acid, glycolic acid, pyruvate, oxalic acid, lactic acid, trifluoroacetic acid, citric acid, fumaric acid, maleic acid, malonic acid, tartaric acid, benzoic acid, cinnamic acid, mandelic acid, emvonic acid, succinic acid, or salicylic acid. Additionally, pharmaceutically acceptable salts may be prepared from the addition of an inorganic base or a free base to a free acid. Salts derived from inorganic bases include, but are not limited to, salts of sodium, potassium, lithium, ammonium, calcium, magnesium, zinc, copper, manganese, and aluminum. Salts derived from organic bases include, but are not limited to, primary, secondary, and tertiary amines, naturally derived substituted amines, substituted amines including cyclic amines, and salts of basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, histidine, caffeine, procaine, hydravamin, choline, betaine, ethylenediamine, glucosamine, methylglucarmin, theobromine, piperazine, N-ethylpiperidine, piperidine, and polyamine resins. Compounds of formula (I) may also exist in the form of amphoteric ions. Pharmaceutically acceptable salts of the compound of chemical formula (I) of particular interest are sodium salts or salts with tertiary amines.
[0074] The term "half maximum effective concentration (EC50 )" refers to the plasma concentration of a specific compound required to obtain 50% of the maximum value of a specific effect in vivo.
[0075] The term "therapeutic effective dose" means an amount of the compound of the present invention, when administered to a subject, that (i) treats or prevents a specific disease, condition, or disorder; (ii) alleviates, improves, or eliminates one or more symptoms of a specific disease, condition, or disorder; or (iii) prevents or delays the onset of one or more symptoms of a specific disease, condition, or disorder as described herein. The therapeutic effective dose may vary depending on the compound, the disease state being treated, the severity of the disease being treated, the age and relative health status of the subject, the route and form of administration, the judgment of the attending physician or veterinarian, and other factors.
[0076] The terms “treatment” or “treating” refer to the application or administration to a patient of a therapeutic agent, i.e., a compound provided herein, intended to cure, alleviate, reduce, alter, treat, improve, enhance, or influence a disease, symptoms of a disease, or the likelihood of developing a disease, or the application or administration of a therapeutic agent to a tissue or cell line isolated from a patient having a disease, symptoms of a disease, or the likelihood of developing a disease (e.g., for diagnosis or in vitro application). Such treatments may be specifically tailored or modified based on knowledge obtained from the field of pharmacogenomics.
[0077] The term "ammonia solution" specifically refers to a solution having a solvent to which ammonia has been added, for example, ammonia may be dissolved in an aqueous solvent or an organic solvent. Ammonia is a compound of nitrogen and hydrogen having the chemical formula NH3. An ammonia solution may be a solution of NH3 in water. A characteristic property of ammonia is that it is basic, meaning it has a pH greater than 7, so that it can form an alkaline solution with water. Additionally, an ammonia solution may be a solution of NH3 in methanol.
[0078] HER2-positive cancer cells have abnormally high levels of HER2 protein. HER2-negative cancer cells do not have abnormal levels of HER2 protein. PD-1-positive cancer cells have abnormally high levels of PD-1 protein. PD-1-negative cancer cells do not have abnormal levels of PD-1 protein.
[0079] The compounds of formula (I) according to the present invention and their pharmaceutically acceptable salts may be used as medicines in the form of pharmaceutical compositions / formulations suitable for intestinal, parenteral, or local administration routes. The medicines may be used for systemic (e.g., parenteral) or local (e.g., local or intralesional injection). The routes of administration of the medicines may be local, parenteral, vaginal, intrauterine, intranasal, or by inhalation.
[0080] Certain tissues may be preferred targets for TLR agonists. In one embodiment, lymph nodes, spleen, bone marrow, blood, tumor sites, and tissues exposed to viruses are preferred sites of administration for the TLR agonist of the present invention.
[0081] Techniques for preparing various dosage forms for parenteral, oral, transdermal, and pulmonary administration are all well known to those skilled in the art. As recognized by those skilled in the art, the effective dose will vary depending on the route of administration, the use of excipients, and the possibility of concomitant use with other therapeutic treatments.
[0082] The “Guidance for Industry and Reviewers Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers,” published by the U.S. Department of Health and Human Services Food and Drug Administration, discloses that the “human equivalent dose” can be obtained by calculation from the following formula:
[0083] HED = Animal Dose (mg / kg) × (Animal Body Weight (kg) / Human Body Weight (kg)) 0.33 .
[0084] Examples
[0085] Preparation of the compound of the present invention
[0086] General synthesis reaction equation
[0087] The compound of chemical formula (I) can be prepared according to the general synthesis reaction formula shown below.
[0088]
[0089]
[0090] Generally, a method for preparing a compound of formula (I) according to the present invention comprises the following steps:
[0091] (a) A step of reacting a compound of the following formula (Ia) with NH2-R1 in the presence of a catalyst to obtain a compound of the following formula (Ib):
[0092]
[0093]
[0094] (Here, R1 and R3 are as defined above);
[0095] (b) A step of reducing the compound of formula (Ib) in the presence of a reducing agent to obtain the compound of formula (Ic) below:
[0096] ,
[0097] (Here, R1 and R3 are as defined above);
[0098] (c) A step of reacting the compound of chemical formula (Ic) with Cl-C(O)-R2 to obtain the compound of chemical formula (Id) below:
[0099] ,
[0100] (Here, R1, R2 and R3 are as defined above); and
[0101] (d) A step of reacting a compound of chemical formula (Id) with an ammonia solution to obtain the desired compound of chemical formula (I) below:
[0102]
[0103] (Here, R1, R2, and R3 are as defined above).
[0104] In step (a), the compound of formula (Ib) can be obtained in the presence of a dichloromethane (DCM) triethylamine (TEA) solution at a temperature of 40°C to 60°C, preferably 50°C to 60°C, or 50°C for at least 1 hour, preferably 1 to 4 hours, more preferably 2 to 3 hours.
[0105] In step (b), the compound of formula (Ib) can be reduced in the presence of Fe / NH4Cl at a temperature of 70°C to 100°C, preferably 80°C to 90°C, or at least 1 hour, preferably 1 to 4 hours, more preferably 2 to 3 hours.
[0106] In step (c), the compound of formula (Ic) can be dissolved in acetonitrile (ACN) and then reacted with Cl-C(O)-R2 at a temperature of 15°C to 35°C or room temperature for at least 1 hour, preferably 1 to 5 hours, more preferably 2 to 4 hours.
[0107] In step (d), the desired compound of formula (I) can be obtained in the presence of an NH3 solution in methanol at 120°C to 180°C, preferably 130°C to 160°C, or 150°C for at least 24 hours, preferably 30 to 50 hours, more preferably 35 to 40 hours.
[0108] The compound of formula (I) according to the present invention can be prepared using the above general reaction formula. Table 2 lists the compounds of the present invention. The synthesis of representative compounds is described in more detail below for illustrative purposes.
[0109] Synthesis of intermediate compound A
[0110]
[0111] compound a1 dissolved in dichloromethane (DCM) containing triethylamine (TEA), and then, at 50°C for 2 hours, the primary amine compound a2 nitroquinoline compounds selectively replaced by a3 provided. Subsequently, the compound a3 The intermediate compound is mixed with EtOH / H2O and reduced by reacting with Fe / NH4Cl at 80°C for 2 hours. A (Reaction Scheme A) was obtained. The obtained intermediate compound A It was used in the following examples.
[0112] Analysis of test compounds
[0113] All reactions Merck 60 F 254Completion was monitored by thin-layer chromatography (TLC) using a plate (20×20 cm) containing silica gel glass, etc. Visual detection of the chromatogram obtained under UV irradiation (254 nm) was performed.
[0114] To analyze the test compound, 1 1H NMR spectra were recorded on a Varian Mercury-400 spectrometer, and chemical shifts were measured in parts per million (ppm). δ It was recorded as ). Multiplicity was recorded as s (single), br s (wide single), d (double), t (triple), q (quadruple), quin (pentuple), sxt (hexauple), and m (multiple). Coupling constant ( J ) is expressed in Hertz. For liquid chromatography-mass spectrometry (LC-MS), electrospray mass spectrometry (ESMS) is obtained using a Waters mass spectrometer. m / z It was recorded as a value. For high-performance liquid chromatography (HPLC), the purity of the final compound was determined by a Waters ACQUITY Arc system using a C18 column (Waters XSelect HSS T3 column, 5 µm, 4.6 mm × 250 mm) operating at 40°C. Elution was performed using water containing 0.1% trifluoroacetic acid and methanol as the mobile phase. The flow rate of the mobile phase was 1 ml / min. Peaks were detected at 210 to 400 nm.
[0115] Compound number 1's synthesis
[0116] 1-(4-amino-2-propyl-1 H -Imidazoo[4,5-c]quinoline-1-yl)-2-methylpropan-2-ol(compound 1 ) was synthesized according to Reaction Scheme 1.
[0117]
[0118] intermediate compound ADissolve in acetonitrile (ACN), and at room temperature for 3 hours, butyryl chloride (compound number 1a React with the corresponding amine compound number 1b was obtained. Compound number 1b reacted with an ammonia solution (7N in methanol) at 150°C for 36 hours, resulting in the formation of an imidazole ring and the replacement of a 4-chloro substituent, compound number 1 The crude product was purified by column chromatography to provide the title compound as a beige solid. 1 ¹H NMR (400 MHz, DMSO- d6 ) δ 8.26 (d, J = 8.0 Hz, 1 H), 7.57 (d, J = 8.0 Hz, 1 H), 7.36 (t, J = 8.0 Hz, 1 H), 7.18 (t, J = 8.0 Hz, 1 H), 6.40 (s, 2 H), 4.78 (s, 1 H), 4.58 (br s, 2 H), 3.00 (t, J = 7.5 Hz, 2 H), 1.82 (sxt, J = 7.4 Hz, 2 H), 1.17 (s, 6 H), 1.00 (t, J = 7.4 Hz, 3 H). LCMS (ESI) m / z 299.3 [M+H] + HPLC Purity: 99.65%.
[0119] Compound number 2's synthesis
[0120] 1-(4-amino-2-pentyl-1 H -Imidazoo[4,5-c]quinoline-1-yl)-2-methylpropan-2-ol(compound 2 ) was synthesized according to reaction scheme 2.
[0121]
[0122] intermediate compound Adissolved in acetonitrile (ACN), and then, hexane chloride oil (compound number) for 3 hours at room temperature 2a React with the corresponding amine compound number 2b was obtained. Compound number 2b reacted with an ammonia solution (7N in methanol) at 150°C for 36 hours, resulting in the formation of an imidazole ring and the replacement of a 4-chloro substituent, compound number 2 The crude product was purified by column chromatography to provide the title compound as a beige powder. 1 ¹H NMR (400 MHz, DMSO- d6 ) δ 8.25 (d, J = 7.8 Hz, 1 H), 7.57 (d, J = 7.8 Hz, 1 H), 7.36 (t, J = 7.8 Hz, 1 H), 7.18 (t, J = 7.8 Hz, 1 H), 6.40 (s, 2 H), 4.78 (s, 2 H), 4.54 (br s, 2 H), 3.01 (t, J = 7.8 Hz, 2 H), 1.80 (quin, J = 7.2 Hz, 2 H), 1.49-1.28 (m, 4 H), 1.17 (s., 6 H), 0.89 (t, J = 7.2 Hz, 3 H). LCMS (ESI) m / z 327.4 [M+H] + HPLC Purity: 99.42%.
[0123] Compound number Synthesis of 9
[0124] 1-(4-amino-2-(4,4,4-trifluorobutyl)-1 H -Imidazoo[4,5-c]quinoline-1-yl)-2-methylpropan-2-ol(compound number 9 ) was synthesized according to reaction scheme 4.
[0125]
[0126] intermediate compound A Dissolve in acetonitrile (ACN) and at room temperature for 3 hours 5,5,5-trifluoropentane oil chloride (compound number 9a React with the corresponding amine compound number 9b was obtained. Compound number 9b reacted with an ammonia solution (7N in methanol) at 150°C for 36 hours, resulting in the formation of an imidazole ring and the replacement of a 4-chloro substituent, compound number 9 The crude product was purified by column chromatography to provide the title compound as a white powder. 1 ¹H NMR (400 MHz, DMSO- d6 ) δ 8.26 (d, J = 7.8 Hz, 1 H), 7.58 (d, J = 7.8 Hz, 1 H), 7.37 (t, J = 7.8 Hz, 1 H), 7.19 (t, J = 7.8 Hz, 1 H), 6.44 (s, 2 H), 4.80 (s, 1 H), 4.55 (br s, 2 H), 3.12 (t, J = 7.5 Hz, 2 H), 2.48-2.34 (m, 2 H), 2.06 (quin, J = 7.5 Hz, 2 H), 1.17 (s., 6 H). LCMS (ESI) m / z 367.4 [M+H] + HPLC Purity: 96.95%.
[0127] Compound number 10 synthesis
[0128] 1-(4-amino-2-(5,5,5-trifluoropentyl)-1 H -Imidazoo[4,5-c]quinoline-1-yl)-2-methylpropan-2-ol(compound number 10 ) was synthesized according to reaction scheme 5.
[0129]
[0130] intermediate compound A Dissolve in acetonitrile (ACN), and at room temperature for 3 hours in 6,6,6-trifluorohexane oil (compound number 10a React with the corresponding amine compound number 10b was obtained. Compound number 10b reacted with an ammonia solution (7N in methanol) at 150°C for 36 hours, resulting in the formation of an imidazole ring and the replacement of a 4-chloro substituent, compound number 10 The crude product was purified by column chromatography to provide the title compound as a white powder. 1 1H NMR (600 MHz, DMSO- d 6) δ 8.26 (d, J = 8.4 Hz, 1H), 7.57 (dd, J = 8.4, 1.2 Hz, 1H), 7.36 (ddd, J = 8.4, 7.0, 1.3 Hz, 1H), 7.20 (ddd, J = 8.4, 7.0, 1.3 Hz, 1H), 6.37 (s, 2H), 4.48 (s, 1H), 4.55 (br s, 2H), 3.06 (t, J = 7.8 Hz, 2H), 2.37-2.29 (m, 2H), 1.90 (midline, J = 7.8 Hz, 2H), 1.64 (Oh Jung-seon, J = 7.8 Hz, 2H), 1.17 (br s, 6H). LCMS (ESI) m / z 381.4 [M+H] + HPLC Purity: 99.34%.
[0131] Using the similar synthesis reaction scheme described above, other compounds listed in Table 2 could be easily produced. For example, using a procedure similar to the synthesis of Compound 1 but utilizing 3-methylbutane oil chloride instead of butyryl chloride, Compound No. 3was prepared. It is similar to the synthesis of compound number 9, but the intermediate compound A Instead, using a procedure utilizing 3-amino-2-chloro-4-((2-hydroxy-2-methylpropyl)amino)quinoline-7-ol, compound number 22 Manufactured.
[0132] In vitro TLR7 and TLR8 agonist activity analysis
[0133] To analyze hTLR7 agonist activity, 3×10 HEK-Blue hTLR7 cells transfected with a secreted fetal alkaline phosphatase (SEAP) reporter were used. 4 Cells were seeded into cells / wells. Cells were seeded at various concentrations of test compounds (compound number 1, 2 , 9 , 10 It was treated with ). Two reference compounds were used for comparison: Reference 1 (Resiquimod, TLR7 / 8 dual agonist) and Reference 2 (1-(4-amino-2-butyl-1 H -Imidazō[4,5-c]quinoline-1-yl)-2-methylpropan-2-ol. Reference 2 It is a more potent TLR7 / 8 dual agonist than resiquimod. Literature [Ganapathi L. et al Refer to . (2015), PLOS ONE, 10(8): e0134640). A SEAP reporter is specially designed to measure placental AP (alkaline phosphatase) secreted from conditioned cell culture media from transfected cells. HEK-Blue hTLR7 cells served to measure the viability of TLR7 via SEAP upon NF-κB activation following TLR7 stimulation.
[0134] To analyze hTLR8 agonist activity, HEK-Blue hTLR8 cells transfected with a SEAP reporter were 3×10 4 Cells were seeded into cells / wells. Cells were treated with various concentrations of test compounds (compound number 1, 2 , 9 ,10 Treated with ). Two reference compounds Reference 1 and Reference 2 HEK-Blue hTLR8 cells were used for comparison. HEK-Blue hTLR8 cells served to measure the viability of TLR8 via SEAP upon NF-κB activation following TLR8 stimulation.
[0135] In the SEAP reporter gene analysis described above, water was used as a negative control. After incubation for approximately 16 hours in 5% CO2 at 37°C, SEAP was determined using a spectrophotometer at a wavelength of 635 nm. The dose-response curve was fitted to a 4-parameter logistic curve (SigmaPlot, version 9.0). ECs of the test compound and the reference compound 50 - The values were calculated. Table 1 shows the analysis results of TLR7 and TLR8 agonist activities.
[0136]
[0137] Table 1 indicates that all test compounds exhibited TLR7 and TLR8 dual agonist activity. In particular, compound number 2 is low EC of TLR7 and TLR8 agonist activity 50 It was the most potent TLR7 / 8 dual agonist due to this. Also, compound number 2 , 9 , 10 of TLR8 EC 50 and TLR7 EC 50 The ratio was lower than that of the two reference compounds, which indicates that these compounds could activate TLR7 and TLR8 with very close efficacy ratios and have the advantage of accurately regulating the activation of TLR7 and TLR8.
[0138] In vitro cytokine profile analysis
[0139] 3 test compounds (compound number 2 , 9 , 10The effect on cytokine induction was evaluated using ). Three reference compounds were used for comparison: Reference 1 (Resiquimod, TLR7 / 8 dual agonist), Reference 2 (1-(4-amino-2-butyl-1 H -Imidaz[4,5-c]quinoline-1-yl)-2-methylpropan-2-ol, TLR7 / 8 dual agonist) and Reference 3 (Motolimod or VTX2337, TLR8 agonist).
[0140] Cryopreserved human PBMCs from four healthy volunteers were purchased from EPBMC® (IMMUNOSPOT®). The PBMCs were thawed at 37°C for 10 minutes and centrifuged at 300×g for 5 minutes at room temperature. The pelleted PBMCs were transferred to RPMI-1640 medium containing 10% FBS and 1% PSA and incubated at 37°C with 5% CO2.
[0141] The test compound and reference compound were dissolved in DMSO, respectively, and subsequently diluted 25-fold with PBS to prepare stock solutions at a concentration of 0.1 mM. Pre-incubated PBMCs were collected and resuspended in fresh RPMI-1640 medium containing 10% FBS and 1% PSA. Approximately 1 × 10⁶ 5PBMCs were added to each well of a 96-well plate and stimulated with 0, 20, or 1000 nM of the test compound at 37°C for 24 hours in a 5% CO2 humidified incubator. The culture supernatant was stored at -20°C for the analysis of TLR7- and TLR8-mediated cytokine induction. PROCARTAPLEX™ immunoassay (Invitrogen) was performed to quantify human IL-6, IL-12p70, and IP-10 in the culture supernatant according to the manufacturer's instructions. Briefly, the culture supernatant samples were thawed on ice and transferred to a microquantification plate. Self-bead-conjugated antibodies specific to the target cytokines were added to the samples for analyte capture. The immobilized target cytokines were specifically detected by biotin-conjugated antibodies and subsequently labeled with streptavidin-phycoerythrin (PE). PE-labeled magnetic beads were detected and verified using a LUMINEX™ 200™ analyzer. Data acquisition, processing, and analysis were performed using XPONENT™ 3.1 software. Target cytokines were normalized to their baseline cytokine levels and presented as relative cytokines.
[0142] FIGS. 1A to 1C are test compounds at various concentrations (compound number 2 , 9 and 10 ) and reference compounds( reference 1 to 3 Represents the relative IL-6 induction from human PBMCs stimulated by ). Compound number 2 , 9 and 10 All of them showed low IL-6-induced activity, and these Reference 1 and 3 It is similar to. These results indicated that the compounds of the present invention do not over-induce IL-6 expression, which is well known to play a role in pathological effects on chronic inflammation and autoimmunity due to the downregulated sustained synthesis of IL-6. In contrast, Reference 2It induced high IL-6 expression when treated at concentrations above 100 nM, particularly above 1000 nM, which is Reference 2 This means that the compound is not suitable for drug development due to the risk of IL-6 overinduction. 2 , 9 , 10 and Reference 2 Based on the structural similarity, low IL-6-induced activity of the compound of the present invention was not expected.
[0143] FIGS. 2A to 2C show test compounds at various concentrations (compound number 2 , 9 and 10 ) and reference compounds( See references 1 to 3 Represents the relative IL-12p70 induction from human PBMCs stimulated by ). Compound number 2 , 9 and 10 All of them exhibited high IL-12p70-inducing activity, but the cytokine IL-12 induced NK cells and CD8 + It is well known to mediate the enhancement of cytotoxic activity and anti-angiogenic activity of cytotoxic T cells.
[0144] FIGS. 3A to 3C show test compounds at various concentrations (compound number 2 , 9 and 10 ) and reference compounds( See references 1 to 3 Represents the relative IP-10 induction from human PBMCs stimulated by ). Compound number 2 , 9 and 10 All of them exhibit high IP-10-induced activity, but the cytokine IP-10 is well known to be involved in inhibiting angiogenesis and is associated with anti-tumor activity.
[0145] Overall, the compounds of the present invention were able to simultaneously activate human TLR7 and TLR8 and increase the expression of IL-12 and IP-10 without over-inducing unwanted IL-6 expression.
[0146]
[0147]
[0148]
[0149]
[0150]
[0151] Toll-like receptor (TLR) ligation activates both the innate and adaptive immune systems and plays a crucial role in antiviral and anti-tumor immunity. The therapeutic potential of TLR agonists includes their use as adjuvants for vaccines, chemotherapy, or standalone therapy. Literature [Engel et. at. (2011), Expert Rev Clin Pharmacol. See , 4(2): 275-289.
[0152] TLR agonists have been widely used as therapeutic or prophylactic agents useful for patients with asthma / allergic rhinitis (AR). As standalone agents, AZD8848 (TLR7 agonist) and VTX-1463 (TLR8 agonist) have demonstrated efficacy in relieving symptoms in AR patients. Imiquimod, or R837 (TLR7 agonist), is an FDA-approved drug used to treat cutaneous basal cell carcinoma, actinic keratosis, and external genital lumps, with numerous suggested off-label benefits in other diseases such as melanoma. Imiquimod has also demonstrated bronchodilator effects in both murine and porcine models of airway hyperresponsiveness (AHR). Imiquimod can also promote antiviral defense and protect against virus-induced airway dysfunction. This appears to be an interesting drug for virus-induced asthma. Resiquimod (TLR7 / 8 dual agonist) is effective in suppressing acute asthma. Literature [Aryan et al. (2014), Int Arch Allergy Immunol.See , 164: 46-63.
[0153] A possible link between toll-like receptor 7 (TLR7) and liver disease has been suggested. The role of TLR7 signaling in liver fibrosis has been demonstrated. Imiquimod (a TLR7 ligand) attenuated lipid accumulation induced by unsaturated fatty acids (UFAs) and reduced lipid peroxidation products induced by UFAs. In vivo experiments performed with TLR7 knockout mice produced results consistent with in vitro experiments. The results support the idea that TLR7 prevented the progression of non-alcoholic fatty liver disease (NAFLD) through induced autophagy and released IGF-1 from the liver. These results suggest a therapeutic strategy for the treatment of NAFLD. See the literature [Kim et al. (2016), Scientific Reports, 6: 27849].
[0154] The anti-tumor activity of TLR7 agonists has been found for tumor types including, but not limited to, squamous cell carcinoma, prostate cancer, bladder cancer, breast cancer, melanoma, glioma, acute myeloid leukemia, breast cancer, T-cell lymphoma, and pancreatic cancer. The anti-tumor activity of TLR8 has been found for tumor types including, but not limited to, glioma, acute myeloid leukemia, breast cancer, T-cell lymphoma, lymphoma, pancreatic cancer, and colon cancer. Literature [Chi et al (2017) Front Pharmacy . Refer to , 8: 304].
[0155] The therapeutic potential / uses of TLR7 / 8 agonists target different diseases, including, but not limited to, the treatment of virus-induced lesions (caused by papillomavirus and herpes simplex virus), primary tumors, cutaneous metastases, antiviral (HCV), and chronic lymphocytic leukemia. Literature [Luke et. al. (2009), Pharmacol Rev. See , 61(2): 177-197.
[0156] TLR7 / 8 agonists stimulate cells via Toll-like receptor (TLR) 7 and 8-dependent pathways, resulting from the activation of an immune response effective against viral and tumor lesions. Resiquimod is a topical drug for viral skin lesions and skin cancers, such as actinic keratosis (AK). AK, also referred to as intraepithelial SCC, is an early-stage skin cancer with the potential to progress to invasive squamous cell carcinoma (SCC) of the skin. Literature [Meyer et al . (2013), Expert Opinion Investigation Drugs [ , 22(1):149-159)]. In conclusion, the compounds of the present invention are TLR7 and TLR8 dual agonists. These compounds exhibit activity in inducing IL-12 and IP-10 expression. TLR 7 / 8 dual agonists are potentially useful medicines as immunomodulators. These compounds can be used to treat diseases or pathologies, but the activation of TLR7 and / or TLR8 provides benefits to patients, for example, for use in treating viral infections, cancer and / or allergic diseases, or for use in activating an immune response effective against these diseases in subjects requiring treatment for viral infections, tumors and / or allergic diseases.
[0157] All references cited and discussed in this specification are incorporated herein by reference in their entirety and to the same extent that each reference is incorporated herein by reference individually.
Claims
Claim 1 A pharmaceutical composition for treating viral infections, cancer, allergic diseases, or liver diseases in subjects requiring treatment, comprising: (a) a TLR7 and TLR8 (TLR7 / 8) dual agonist selected from the group consisting of the following compound 2; the following compound 9; the following compound 10; and pharmaceutically acceptable salts thereof; and (b) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and / or adjuvant. Claim 2 In claim 1, the TLR7 / 8 dual agonist is 1-(4-amino-2-pentyl-1 H A pharmaceutical composition comprising -imidazo[4,5-c]quinoline-1-yl)-2-methylpropan-2-ol or a pharmaceutically acceptable salt thereof. Claim 3 A pharmaceutical composition for treating viral infections, cancer, allergic diseases, or liver diseases in subjects requiring treatment, comprising a TLR7 / 8 dual agonist having the chemical structure of the following compound 2 or a pharmaceutically acceptable salt thereof: . Claim 4 A pharmaceutical composition for treating allergic rhinitis, asthma, alcoholic fatty liver disease, or non-alcoholic fatty liver disease in subjects requiring treatment, comprising a TLR7 / 8 dual agonist having the chemical structure of the following compound 2 or a pharmaceutically acceptable salt thereof: . Claim 5 A pharmaceutical composition for treating allergic rhinitis, asthma, alcoholic fatty liver disease, or non-alcoholic fatty liver disease in subjects requiring treatment, comprising: (a) a TLR7 and TLR8 (TLR7 / 8) dual agonist selected from the group consisting of the following compound 2; the following compound 9; the following compound 10; and pharmaceutically acceptable salts thereof; and (b) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and / or adjuvant. Claim 6 A pharmaceutical composition for activating an effective immune response against viral infection, cancer, allergic disease, or liver disease in a subject requiring it, comprising a TLR7 / 8 dual agonist having the chemical structure of the following compound 2 or a pharmaceutically acceptable salt thereof: . Claim 7 A pharmaceutical composition for activating an immune response effective against viral infection, cancer, allergic disease, or liver disease in a subject requiring it, comprising: (a) a TLR7 and TLR8 (TLR7 / 8) dual agonist selected from the group consisting of the following compound 2; the following compound 9; the following compound 10; and pharmaceutically acceptable salts thereof; and (b) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and / or adjuvant. Claim 8 A medicine for treating viral infections, cancer, allergic diseases, or liver diseases in subjects requiring treatment, comprising a TLR7 / 8 dual agonist having the chemical structure of the following compound 2 or a pharmaceutically acceptable salt thereof: . Claim 9 As a medicine for treating viral infections, cancer, allergic diseases, or liver diseases in subjects requiring treatment, (a) a TLR7 and TLR8 (TLR7 / 8) dual agonist selected from the group consisting of the following compound 2; the following compound 9; the following compound 10; and pharmaceutically acceptable salts thereof; and (b) A medicine comprising a pharmaceutically acceptable carrier and / or adjuvant. Claim 10 A medicine for treating allergic rhinitis, asthma, alcoholic fatty liver disease, or non-alcoholic fatty liver disease in subjects requiring it, comprising a TLR7 / 8 dual agonist having the chemical structure of compound 2 below or a pharmaceutically acceptable salt thereof: . Claim 11 A medicine for treating allergic rhinitis, asthma, alcoholic fatty liver disease, or non-alcoholic fatty liver disease in subjects requiring it, comprising: (a) a TLR7 and TLR8 (TLR7 / 8) dual agonist selected from the group consisting of the following compound 2; the following compound 9; the following compound 10; and pharmaceutically acceptable salts thereof; and (b) A medicine comprising a pharmaceutically acceptable carrier and / or adjuvant. Claim 12 A medicine for activating an effective immune response against viral infection, cancer, allergic disease, or liver disease in subjects requiring it, comprising a TLR7 / 8 dual agonist having the chemical structure of the following compound 2 or a pharmaceutically acceptable salt thereof: . Claim 13 As a medicine for activating an effective immune response against viral infection, cancer, allergic disease, or liver disease in a subject requiring it, (a) a TLR7 and TLR8 (TLR7 / 8) dual agonist selected from the group consisting of the following compound 2; the following compound 9; the following compound 10; and pharmaceutically acceptable salts thereof; and (b) A medicine comprising a pharmaceutically acceptable carrier and / or adjuvant. Claim 14 A pharmaceutical composition of claim 1, 3, 6, or 7, or a medicine of claim 8, 9, 12, or 13, wherein the cancer is a cancer selected from the group consisting of esophagus, stomach, colon, rectum, pancreas, lung, breast, cervix, uterine body, ovary, bladder, head and neck, endometrium, osteosarcoma, prostate, and neuroblastoma. Claim 15 A pharmaceutical composition of claim 1, 3, 6, or 7, or a medicine of claim 8, 9, 12, or 13, wherein the allergic disease is allergic rhinitis or asthma, and the liver disease is alcoholic fatty liver disease or non-alcoholic fatty liver disease. Claim 16 delete
Citation Information
Patent Citations
4-amino-imidazoquinoline compounds
JP2017513883A
1-alkoxy 1h-imidazo ring systems and methods
WO2006028962A2
Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom
WO2012167081A1
4-amino-imidazoquinoline compounds
WO2015162075A1
